These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 9820396

  • 1. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
    Straub RH, Vogl D, Gross V, Lang B, Schölmerich J, Andus T.
    Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
    [Abstract] [Full Text] [Related]

  • 2. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C, Backmerhoff F, Schumacher B, Niederau C.
    Hepatogastroenterology; 1997 Nov; 44(13):90-107. PubMed ID: 9058126
    [Abstract] [Full Text] [Related]

  • 3. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis.
    Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M.
    Arthritis Rheum; 2002 Mar; 46(3):654-62. PubMed ID: 11920401
    [Abstract] [Full Text] [Related]

  • 4. The circulating common gamma chain (CD132) in inflammatory bowel disease.
    Nielsen OH, Kirman I, Johnson K, Giedlin M, Ciardelli T.
    Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
    [Abstract] [Full Text] [Related]

  • 5. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J, Subrt I, Dìdek P, Siala K, Schwarz J, Machalová V, Varvarovská J, Pazdiora P, Pozler O, Stozický F.
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [Abstract] [Full Text] [Related]

  • 6. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 7. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
    Nielsen OH, Ciardelli T, Wu Z, Langholz E, Kirman I.
    Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
    [Abstract] [Full Text] [Related]

  • 8. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
    Eivindson M, Grønbaek H, Flyvbjerg A, Frystyk J, Zimmermann-Nielsen E, Dahlerup JF.
    Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
    [Abstract] [Full Text] [Related]

  • 9. Resistin is an inflammatory marker of inflammatory bowel disease in humans.
    Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, Parhofer KG, Göke B, Broedl UC.
    Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831
    [Abstract] [Full Text] [Related]

  • 10. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
    Caradonna L, Amati L, Lella P, Jirillo E, Caccavo D.
    Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
    [Abstract] [Full Text] [Related]

  • 11. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L, Schaper L, Buning C, Hengstermann S, Koernicke T, Tillinger W, Guglielmi FW, Norman K, Buhner S, Ockenga J, Pirlich M, Lochs H.
    Nutrition; 2008 Jun; 24(7-8):694-702. PubMed ID: 18499398
    [Abstract] [Full Text] [Related]

  • 12. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN.
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [Abstract] [Full Text] [Related]

  • 13. Mean platelet volume: a useful marker of inflammatory bowel disease activity.
    Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA.
    Am J Gastroenterol; 2001 Mar; 96(3):776-81. PubMed ID: 11280550
    [Abstract] [Full Text] [Related]

  • 14. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [Abstract] [Full Text] [Related]

  • 15. Seizure frequency and cortisol and dehydroepiandrosterone sulfate (DHEAS) levels in women with epilepsy receiving antiepileptic drug treatment.
    Galimberti CA, Magri F, Copello F, Arbasino C, Cravello L, Casu M, Patrone V, Murialdo G.
    Epilepsia; 2005 Apr; 46(4):517-23. PubMed ID: 15816945
    [Abstract] [Full Text] [Related]

  • 16. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease.
    Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV.
    Growth Horm IGF Res; 2001 Dec; 11(6):364-7. PubMed ID: 11914023
    [Abstract] [Full Text] [Related]

  • 17. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group.
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [Abstract] [Full Text] [Related]

  • 18. Antioxidant and immune status in active Crohn's disease. A possible relationship.
    Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B.
    Clin Nutr; 2000 Feb; 19(1):43-8. PubMed ID: 10700533
    [Abstract] [Full Text] [Related]

  • 19. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases.
    Ludwiczek O, Kaser A, Tilg H.
    Int J Colorectal Dis; 2003 Mar; 18(2):142-7. PubMed ID: 12548417
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.